Skip to main content

Advertisement

Table 2 Parameters used in the study, children ≥ 5 years and adults

From: Strict adherence to malaria rapid test results might lead to a neglect of other dangerous diseases: a cost benefit analysis from Burkina Faso

EPIDEMIOLOGICAL PARAMETERS   Source1
Malaria attributable fevers (MAF)/febrile patients (dry season) 1.7% Primary
Malaria attributable fevers (MAF)/febrile patients (rainy season) 25.1% Primary
Malaria parasite density > 40,000/μL (both seasons) 36.8% Primary
Death rate treated MAF, high parasite density 0.0% Primary
Excess death rate untreated MAF, high parasite density 0.4% Assumption
Excess death rate untreated MAF low parasite density 0.0% Assumption
Excess death rate untreated MAF in RDT neg 0.0% Assumption
Death rate treated NMFI 0.84% Primary
Proportion of potentially fatal non malarial fever (PFNM) 20% Assumption
Excess death rate untreated PFNM 7% Assumption
CASE MANAGEMENT, PRESUMPTIVE BRANCH, ADULTS   
Anti-malarial treatment among MAF 97% Primary
Anti-malarial treatment among MAF, high parasite density 97.3% Primary
Anti-malarial treatment among MAF, low parasite density 97% Assumption
Anti-malarial treatment among those treated with antibiotics 79.3% Primary
Anti-malarial treatment among those not treated with antibiotics 94.8% Primary
Antibiotic treatment among NMFI 56.1% Primary
Antibiotic treatment among PFMN 90% Assumption
Antibiotic treatment among patients presumptively treated for malaria 47.1% Primary
Antibiotic treatment among PFMN presumptively treated for malaria 86% Assumption
Antibiotic treatment among patients not presumptively treated for malaria 80.8% Primary
Antibiotic treatment among PFMN not treated for malaria 99% Assumption
CASE MANAGEMENT, RDT, ADULTS   
Anti-malarial treatment among RDT+, high parasite density (hpd) 100% Primary
Anti-malarial treatment among RDT+, low parasite density (lpd) 96.4% Primary
Anti-malarial treatment among RDT- 10% Assumption
Antibiotic treatment among RDT+ 42.5% Primary
Antibiotic treatment among PFNM RDT+ 86% Assumption
Antibiotic treatment among RDT- 77.4% Assumption
Antibiotic treatment among PFNM RDT- 98.6% Assumption
RDT ACCURACY, ADULTS   
RDT sensitivity, malaria attributable fever (MAF), lpd, dry season 91.6% Primary
RDT specificity, malaria attributable fever (MAF), dry season 78.7% Primary
RDT sensitivity, malaria attributable fever (MAF), lpd, rainy season 95.3% Primary
RDT specificity, malaria attributable fever (MAF), rainy season 77.4% Primary
RDT sensitivity, MAF, high parasite density 99% Primary
COSTS, ADULTS   
Cost of RDT 0.71 (ref. 26)
Cost of anti-malarial treatment, Coartem (average, €) 2 (ref. 26)
Cost of antibiotic treatment (average, €) 0.4 Estimate
Life Value (€) corresponding to 25 US $*YLL 525 (see text)
Life Value (€) corresponding to 150 US $*YLL 3150 (see text)
  1. 1 Primary data obtained from previous RCT (ref. 15) and from previous assessment of the RDT accuracy (ref. 14); assumptions based on estimates from primary data, expert opinion and previous literature (see explanation in text)